Bexsero Vaccine Against MenB Bacteria Only Effective in 50% of aHUS Patients, Study Finds
Bexsero, a vaccine developed as a treatment for serogroup B meningococci — the bacteria that can cause meningitis — is only effective in 50% of people with atypical hemolytic uremic syndrome (aHUS), a new study reports. The study, “Low efficacy of vaccination against serogroup…